TNDM Earnings Date: Nov 5, 2026 (Estimated) — Tandem Diabetes Care, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is TNDM's next earnings date?
Tandem Diabetes Care, Inc. (TNDM) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.25 on revenue of $265.8M.
How did TNDM do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Tandem Diabetes Care, Inc. posted EPS of -$0.31 versus the -$0.32 estimate, a beat of 6.1%. Revenue was $254.6M against a $255.0M estimate. The stock's 1-day post-earnings move was +19.1%.
How much does TNDM stock move after earnings?
TNDM beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 20.8% (up or down) in the day after earnings.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.32 | -0.31 | +6.06% | $254.6M | ✅ Beat | +19.11% | +23.10% | +5.91% |
| 2026-05-07 | Q1 2026 | -0.45 | -0.30 | +33.33% | $247.2M | ✅ Beat | -16.19% | -23.39% | +0.00% |
| 2026-02-19 | Q4 2025 | -0.07 | -0.01 | +85.71% | $290.4M | ✅ Beat | +32.67% | +39.25% | +34.02% |
| 2025-11-06 | Q3 2025 | -0.33 | -0.31 | +6.06% | $249.3M | ✅ Beat | +21.98% | +31.51% | +55.59% |
| 2025-08-06 | Q2 2025 | -0.40 | -0.78 | -95.00% | $240.7M | ❌ Miss | -19.94% | -22.65% | -12.58% |
| 2025-04-30 | Q1 2025 | -0.61 | -0.67 | -9.02% | $234.4M | ❌ Miss | +18.58% | +32.11% | +17.63% |
| 2025-02-26 | Q4 2024 | -0.24 | -0.44 | -83.33% | $282.6M | ❌ Miss | -35.25% | -43.11% | -41.02% |
| 2024-11-06 | Q3 2024 | -0.40 | -0.36 | +10.00% | $244.0M | ✅ Beat | -2.69% | -13.35% | -12.06% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $254.6M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Supplies and Other | 55.0% | $139.9M | +8.6% | $128.1M | $132.3M | $128.8M | $139.1M |
| Pump | 45.0% | $114.7M | +2.5% | $114.8M | $102.1M | $111.9M | $110.1M |
By region
Q2 FY26 · $254.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 70.4% | $179.3M | +5.3% | $214.6M | $150.6M | $170.2M | $175.6M |
| Non-US | 29.6% | $75.3M | +6.8% | $68.1M | $83.8M | $70.5M | $73.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.